Visium Asset Management, led by Jacob Gottlieb, has added NephroGenex Inc (NASDAQ:NRX) and Ignyta Inc (OTCBB:RXDX) to its equity portfolio. According to a filing with the Securities and Exchange Commission, Jacob Gottlieb’s fund holds around 476,491 shares of NephroGenex, the passive stake amassing 5.4% of the common stock.
NephroGenex Inc (NASDAQ:NRX) is a drug development company that focuses on novel therapies for kidney disease. The company went public last week, issuing 3.1 million shares at a price of $12 apiece. A 45-day option to purchase an additional amount of 465,000 shares has also been granted to the underwriters.
In the second filing, Visium Asset Management reported ownership of 833,300 shares of Ignyta Inc (OTCBB:RXDX). Currently the position amasses around 6.2% of the company’s common stock.
In the fourth quarter of last year, Visium Asset Management, revealed boosting its position in Zogenix, Inc. (NASDAQ:ZGNX) to 8.9 million shares, from 1.7 million held at the end of the previous quarter, the fund revealed owning 9.11 million shares of Zogenix, Inc. at the end of the fourth quarter. Jacob Gottlieb also upped its stake in QLT Inc. (USA) (NASDAQ:QLTI) to 3.5 million shares, from 2.0 million shares held earlier.
Allergan, Inc. (NYSE:AGN), stands on the first spot in Jacob Gottlieb’s equity portfolio, where the fund has invested 5.77% of its equity portfolio amassing 2.65 million shares. The fund also initiated a position in Watson Pharmaceuticals Inc (WPI) in the fourth quarter and now owns 1.46 million shares, worth $245.69 million.